Related Experiment Video

Updated: May 16, 2025

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

20.7K

Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy

Rinzhin T Sherpa1, Cynthia J Koziol-White1, Reynold A Panettieri1

  • 1Rutgers Institute for Translational Medicine and Science, Rutgers University, 89 French Street, New Brunswick, NJ 08901, USA.

Cells
|May 13, 2025
PubMed

Insights

Dual phosphodiesterase (PDE) inhibitors offer new hope for obstructive airway diseases like asthma and COPD. Ensifentrine, a new FDA-approved dual PDE3/4 inhibitor, improves bronchodilation and reduces inflammation with better safety outcomes.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Molecular Biology

Background:

  • Obstructive airway diseases (OADs), including asthma and COPD, are major global health issues characterized by airway inflammation and obstruction.
  • Shared molecular mechanisms and therapeutic responses link these distinct diseases, highlighting common pathways.
  • Cyclic AMP (cAMP) is vital for airway smooth muscle relaxation, but phosphodiesterase (PDE) enzymes degrade cAMP, posing a therapeutic target.

Purpose of the Study:

  • To explore the role of PDE inhibitors in managing OADs.
  • To evaluate the potential of novel PDE inhibitors with improved safety profiles.
  • To highlight the significance of Ensifentrine in advancing COPD treatment.

Main Methods:

  • Review of the pathophysiology of OADs and the role of cAMP.
  • Analysis of challenges and successes in developing PDE inhibitors.
  • Examination of the clinical profile and FDA approval of Ensifententrine.

Main Results:

  • PDE inhibitors target cAMP degradation, aiming to enhance airway smooth muscle relaxation.
  • Previous PDE inhibitors faced clinical failures due to adverse side effects.
  • Ensifentrine, a dual PDE3/4 inhibitor, demonstrates improved bronchodilation, reduced inflammation, and fewer exacerbations in COPD.

Conclusions:

  • Developing PDE inhibitors with enhanced safety profiles is crucial for add-on therapy in severe asthma and COPD.
  • Ensifentrine represents a significant advancement in COPD management due to its efficacy and safety.
  • Targeting PDE enzymes offers a promising strategy for treating obstructive airway diseases.
Keywords:
AsthmaCOPDPDEcAMPensifentrine

More Related Videos

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.1K
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

19.6K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
104
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
124
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
103
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
284
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
110